Literature DB >> 4552131

Evaluating the long-term need for antiparkinson drugs by chronic schizophrenics.

C J Klett, E Caffey.   

Abstract

Mesh：

Substances：

Year:  1972        PMID： 4552131     DOI： 10.1001/archpsyc.1972.01750220084016

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN： 0003-990X


× No keyword cloud information.
  13 in total

1.  Assessment of drugs in schizophrenia. Discussion on assessment of drug-induced extrapyramidal reactions.

Authors:  H A McClelland
Journal:  Br J Clin Pharmacol       Date:  1976-06       Impact factor: 4.335

2.  Extrapyramidal effects of neuroleptics.

Authors:  A D Korczyn; G J Goldberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  1976-09       Impact factor: 10.154

3.  Issues in developing quality aftercare clinics for the chronic mentally ill.

Authors:  P T Donlon; R T Rada
Journal:  Community Ment Health J       Date:  1976

Review 4.  Clinical use of psychotherapeutic drugs. I. Antipsychotic and antimanic drugs.

Authors:  L E Hollister
Journal:  Drugs       Date:  1972       Impact factor: 9.546

5.  Limitations on quality assurance effectiveness: Improving psychiatric inpatient drug prescribing habits of physicians.

Authors:  S R Eastaugh
Journal:  J Med Syst       Date:  1980       Impact factor: 4.460

6.  Anticholinergic drug abuse: a common problem?

Authors:  G P Pullen; N R Best; J Maguire
Journal:  Br Med J (Clin Res Ed)       Date:  1984-09-08

Review 7.  Management of the schizophrenic patient.

Authors:  M V Seeman
Journal:  Can Med Assoc J       Date:  1979-05-05       Impact factor: 8.262

8.  Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia.

Authors:  Julie Eve Desmarais; Linda Beauclair; Lawrence Annable; Marie-Claire Bélanger; Theodore T Kolivakis; Howard C Margolese
Journal:  Ther Adv Psychopharmacol       Date:  2014-12

9.  31P magnetic resonance spectroscopy of the medial temporal lobe of schizophrenic patients with neuroleptic-resistant marked positive symptoms.

Authors:  H Fukuzako; K Takeuchi; K Ueyama; T Fukuzako; Y Hokazono; K Hirakawa; K Yamada; T Hashiguchi; M Takigawa; T Fujimoto
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

10.  Regional analysis of neostriatal cholinergic and dopaminergic receptor binding and tyrosine hydroxylase activity as a function of aging.

Authors:  R Strong; J C Waymire; T Samorajski; Z Gottesfeld
Journal:  Neurochem Res       Date:  1984-11       Impact factor: 3.996
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.